Previous 10 | Next 10 |
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Feb. 26, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2019 . Full year net revenue decreased 11% to $1,449 million...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Feb. 25, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz , President and Chief Operating Officer of United Therapeutics, will participate in a fireside chat covering th...
United Therapeutics (NASDAQ: UTHR ) +6.5% pre-market after announcing a preliminary analysis indicates the INCREASE clinical study of its Tyvaso (treprostinil) inhalation solution met its primary efficacy endpoint of demonstrating improvement in a six-minute walk distance. More ne...
RESEARCH TRIANGLE PARK, N.C. and MANCHESTER, N.H. , Feb. 24, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) and DEKA Research & Development Corp. today announced receipt of an additional 510(k) clearance by the U.S. Food and Drug Administration (FDA) related to ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Feb. 24, 2020 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that preliminary analysis indicates that the INCREASE clinical study of Tyvaso ® (treprostinil) Inhalation Solution in patients su...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Feb. 19, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2019 financial results before the market opens on Wednesday, February 26, 2020 . ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Feb. 4, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced that on January 29, 2020 , the United States District Court for the District of New Jersey issued a decision in favor of United Therapeutics a...
United Therapeutics (NASDAQ: UTHR ) announces that Unituxin (dinutuximab) failed to achieve the primary endpoint in a Phase 2/3 clinical trial, DISTINCT , evaluating the GD-2 targeting monoclonal antibody, combined with chemo agent irinotecan, in patients with relapsed/refractory small ce...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Feb. 3, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced topline results from the phase 2/3 DISTINCT clinical study evaluating Unituxin ® (dinutuximab) Injection added to irinoteca...
AdaptHealth (NASDAQ: AHCO ) initiated with Buy rating and $17 (31% upside) price target at Stifel. More news on: AdaptHealth Corp., DURECT Corporation, InMed Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...